-+ 0.00%
-+ 0.00%
-+ 0.00%

Bristol Myers Squibb to Present Phase 2 Pumitamig Lung Cancer Data at ESMO 2026

PUBT·10/19/2026 11:06:14
Bristol Myers Squibb to Present Phase 2 Pumitamig Lung Cancer Data at ESMO 2026
  • Bristol Myers Squibb will present cancer trial data at ESMO 2026 in Madrid, October 23-27, including two late-breaking Phase 3 iza-bren studies.
  • Iza-bren presentations will cover previously treated breast cancer and EGFR-mutant lung cancer; Biokin sponsored both Phase 3 trials.
  • Pumitamig, jointly developed with BioNTech, will feature in late-breaking global Phase 2 findings evaluating treatment for metastatic lung cancer.
  • Final overall survival results from CheckMate 8HW will compare Opdivo with Yervoy against Opdivo alone or chemotherapy in metastatic colorectal cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20261016505356) on October 19, 2026, and is solely responsible for the information contained therein.